PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30056902-0 2018 Malnutrition Risk in Kidney Recipients Treated With Mycophenolate Mofetil Is Associated With IMPDH1 rs2278294 Polymorphism. Mycophenolic Acid 52-73 inosine monophosphate dehydrogenase 1 Homo sapiens 93-99 30056902-4 2018 STUDY DESIGN: In an observational longitudinal study of kidney transplant recipients treated with mycophenolate mofetil, genetic factors were IMPDH1 (rs2278294, rs2278293) and IMPDH2 (rs11706052) allelic variants, the main outcome was the time-dependent change in BMI, and secondary outcomes were occurrence of BMI below 18.5 or 20 kg/m2. Mycophenolic Acid 98-119 inosine monophosphate dehydrogenase 1 Homo sapiens 142-148 20136638-0 2010 Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. Mycophenolic Acid 78-95 inosine monophosphate dehydrogenase 1 Homo sapiens 15-21 20649757-0 2010 Inosine 5"-monophosphate dehydrogenase 1 haplotypes and association with mycophenolate mofetil gastrointestinal intolerance in pediatric heart transplant patients. Mycophenolic Acid 73-94 inosine monophosphate dehydrogenase 1 Homo sapiens 0-40 20718729-0 2010 Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. Mycophenolic Acid 24-41 inosine monophosphate dehydrogenase 1 Homo sapiens 87-93 20718729-1 2010 BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA). Mycophenolic Acid 146-163 inosine monophosphate dehydrogenase 1 Homo sapiens 73-79 20718729-1 2010 BACKGROUND AND PURPOSE: Inosine monophosphate dehydrogenases, encoded by IMPDH1 and IMPDH2, are targets for the important immunosuppressive drug, mycophenolic acid (MPA). Mycophenolic Acid 165-168 inosine monophosphate dehydrogenase 1 Homo sapiens 73-79 19010451-0 2009 Expression of IMPDH1 is regulated in response to mycophenolate concentration. Mycophenolic Acid 49-62 inosine monophosphate dehydrogenase 1 Homo sapiens 14-20 20431509-4 2010 There are also genetic predictors of pharmacodynamics, including IMPDH1 for mycophenolate and ABCB1 for cyclosporine that may identify individuals at particular risk of efficacy failure or toxicity with a given drug. Mycophenolic Acid 76-89 inosine monophosphate dehydrogenase 1 Homo sapiens 65-71 35524809-2 2022 METHODS: PubMed, Web of Science, Embase, Cochrane Library, Wanfang Data, and the China Academic Journal Network Publishing Database were systematically searched for studies investigating the associations of IMPDH1, IMPDH2, and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking MPA. Mycophenolic Acid 302-305 inosine monophosphate dehydrogenase 1 Homo sapiens 207-213 17851563-1 2008 Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA). Mycophenolic Acid 179-196 inosine monophosphate dehydrogenase 1 Homo sapiens 0-40 17851563-1 2008 Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA). Mycophenolic Acid 179-196 inosine monophosphate dehydrogenase 1 Homo sapiens 42-48 17851563-1 2008 Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA). Mycophenolic Acid 198-201 inosine monophosphate dehydrogenase 1 Homo sapiens 0-40 17851563-1 2008 Inosine 5"-monophosphate dehydrogenase 1 (IMPDH1) catalyzes the rate-limiting step of the de novo pathway for purine synthesis and is a major target of the immunosuppressive drug mycophenolic acid (MPA). Mycophenolic Acid 198-201 inosine monophosphate dehydrogenase 1 Homo sapiens 42-48 17713475-1 2008 The objective of the study was to evaluate the effect of mycophenolate mofetil (MMF) on the regulation of inosine monophosphate dehydrogenase (IMPDH) during the first 2 years after renal transplantation. Mycophenolic Acid 57-78 inosine monophosphate dehydrogenase 1 Homo sapiens 143-148 17713475-1 2008 The objective of the study was to evaluate the effect of mycophenolate mofetil (MMF) on the regulation of inosine monophosphate dehydrogenase (IMPDH) during the first 2 years after renal transplantation. Mycophenolic Acid 80-83 inosine monophosphate dehydrogenase 1 Homo sapiens 143-148 18192912-10 2008 Two weeks posttransplant, MPA-treated patients displayed elevated IMPDH 1 and 2 in reticulocytes, suggesting enzyme induction in these cells during prolonged MPA therapy. Mycophenolic Acid 26-29 inosine monophosphate dehydrogenase 1 Homo sapiens 66-79 8632430-0 1996 Nuclear magnetic resonance and molecular modeling study on mycophenolic acid: implications for binding to inosine monophosphate dehydrogenase. Mycophenolic Acid 59-76 inosine monophosphate dehydrogenase 1 Homo sapiens 106-141 8632430-1 1996 The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described. Mycophenolic Acid 39-56 inosine monophosphate dehydrogenase 1 Homo sapiens 86-121 8632430-1 1996 The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described. Mycophenolic Acid 39-56 inosine monophosphate dehydrogenase 1 Homo sapiens 123-127 8632430-1 1996 The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described. Mycophenolic Acid 58-61 inosine monophosphate dehydrogenase 1 Homo sapiens 86-121 8632430-1 1996 The conformation of the sodium salt of mycophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from 1D DIFNOE and 2D ROESY experiments in water and molecular dynamics (MD) is described. Mycophenolic Acid 58-61 inosine monophosphate dehydrogenase 1 Homo sapiens 123-127 1677450-3 1991 In the present in vitro study, the formation in human T cells (MOLT-4, ATH8, and CCRF-CEM) of the pharmacologically active metabolite of ddIno and ddAdo, 2",3"-dideoxyadenosine-5"-triphosphate (ddATP), was found to be stimulated 2-4-fold by appropriate concentrations of inosinate dehydrogenase (IMPD) inhibitors such as ribavirin, tiazofurin, and mycophenolic acid. Mycophenolic Acid 348-365 inosine monophosphate dehydrogenase 1 Homo sapiens 296-300 34188518-0 2021 Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 -106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients. Mycophenolic Acid 87-104 inosine monophosphate dehydrogenase 1 Homo sapiens 47-53 17463174-10 2007 Changes in IMPDH1 and 2 expression were observed in patient samples after initiation of an immunosuppressive regimen that included calcineurin inhibitors, mycophenolate mofetil, and steroids. Mycophenolic Acid 155-176 inosine monophosphate dehydrogenase 1 Homo sapiens 11-23 35524809-8 2022 CONCLUSIONS: IMPDH1, IMPDH2, and UGT1A9 polymorphisms were associated with rejection in kidney transplant recipients, and the genetic backgrounds of patients should be considered when using MPA. Mycophenolic Acid 190-193 inosine monophosphate dehydrogenase 1 Homo sapiens 13-19 33524926-0 2021 Effect of inosine monophosphate dehydrogenase-1 gene polymorphisms on mycophenolate mofetil effectiveness in neuromyelitis optica spectrum disorder patients. Mycophenolic Acid 70-91 inosine monophosphate dehydrogenase 1 Homo sapiens 10-47 33524926-2 2021 This research investigated the association between the gene polymorphism of inosine monophosphate dehydrogenase-1 and effectiveness of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorder patients. Mycophenolic Acid 135-156 inosine monophosphate dehydrogenase 1 Homo sapiens 76-113 33524926-1 2021 BACKGROUND: Inosine monophosphate dehydrogenase-1 is the target of mycophenolate mofetil. Mycophenolic Acid 67-88 inosine monophosphate dehydrogenase 1 Homo sapiens 12-49